Immunomodulators and risk for breakthrough infection after third COVID-19 mRNA vaccine among patients with rheumatoid arthritis: A cohort study

OBJECTIVES: To investigate COVID-19 breakthrough infection after third mRNA vaccine dose among patients with RA by immunomodulator drug class, and we hypothesized that CD20 inhibitors (CD20i) would have higher risk for breakthrough COVID-19 vs. TNF inhibitors (TNFi). METHODS: We performed a retrospe...

Descripción completa

Detalles Bibliográficos
Autores principales: Schiff, Abigail E., Wang, Xiaosong, Patel, Naomi J., Kawano, Yumeko, Kowalski, Emily N., Cook, Claire E., Vanni, Kathleen M.M., Qian, Grace, Bade, Katarina J., Saavedra, Alene A., Srivatsan, Shruthi, Williams, Zachary K., Venkat, Rathnam K., Wallace, Zachary S., Sparks, Jeffrey A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10592996/
https://www.ncbi.nlm.nih.gov/pubmed/37873462
http://dx.doi.org/10.1101/2023.10.08.23296717

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10592996/
https://www.ncbi.nlm.nih.gov/pubmed/37873462
http://dx.doi.org/10.1101/2023.10.08.23296717

Ejemplares similares